Merck’s Keytruda gets boost in kidney and head and neck cancerMerck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Share XMerck’s Keytruda gets boost in kidney and head and neck cancerhttps://pharmaphorum.com/news/mercks-keytruda-gets-boost-in-kidney-and-head-and-neck-cancer/
FDA accepts Merck & Co’s two new antibacterial drug applicationsThe FDA has accepted two new antibacterial drug applications from Merck & Co, both of which have received Share XFDA accepts Merck & Co’s two new antibacterial drug applicationshttps://pharmaphorum.com/news/fda-accepts-merck-cos-two-new-antibacterial-drug-applications/
FDA approves Samsung/Merck & Co’s Herceptin biosimilarThe FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck Share XFDA approves Samsung/Merck & Co’s Herceptin biosimilarhttps://pharmaphorum.com/news/fda-approves-samsung-merck-cos-herceptin-biosimilar/
FDA extends review of Merck & Co’s Keytruda in lung cancer useUS regulators have pushed back the deadline for their review of Merck & Co’s immunotherapy Keytruda in certain Share XFDA extends review of Merck & Co’s Keytruda in lung cancer usehttps://pharmaphorum.com/news/fda-review-merck-keytruda-lung-cancer/
AZ/Merck & Co get new US use for ovarian cancer drugAfter several disappointments this year AstraZeneca has ended 2018 on a positive note, gaining a new use for Share XAZ/Merck & Co get new US use for ovarian cancer drughttps://pharmaphorum.com/news/astrazeneca-merck-lynparza-roxadustat/
2018 in review: Merck & Co sets new standards in oncology, CAR-Ts hit EU marketOncology drugs are developing at a fast pace, but 2018 was the year when immune-oncology set new standards Share X2018 in review: Merck & Co sets new standards in oncology, CAR-Ts hit EU markethttps://pharmaphorum.com/views-analysis-oncology/2018-in-review-merck-co-sets-new-standards-in-oncology-car-ts-hit-eu-market/
Merck to buy animal health firm Antelliq for $2.4bnMerck & Co is to buy animal health firm Antelliq Group for $2.4 billion in a bid to Share XMerck to buy animal health firm Antelliq for $2.4bnhttps://pharmaphorum.com/news/merck-to-buy-animal-health-firm-antelliq-for-2-4bn/
FDA breakthrough designation for Bayer and Merck & Co’s AI softwareBayer and Merck & Co have won a breakthrough device designation from the US regulator FDA for artificial Share XFDA breakthrough designation for Bayer and Merck & Co’s AI softwarehttps://pharmaphorum.com/news/fda-breakthrough-designation-bayer-merck-ai/
NHS funds BMS’ Opdivo to prevent skin cancer returningNICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer Share XNHS funds BMS’ Opdivo to prevent skin cancer returninghttps://pharmaphorum.com/news/nhs-funds-bms-opdivo-to-prevent-skin-cancer-returning/
